Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 14, 2026, 7:41 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1105–1128 of 12,548 matching trials from the live ClinicalTrials.gov search.

Filters: Miami, Florida Clear all

Conditions: Chronic Inflammatory Demyelinating Polyneuropathy
Interventions: Immune globulin (human) 10% solution for intravenous administration; Biological
Lead sponsor: Kedrion S.p.A.; Industry
Eligibility: 18 Years and older
Enrollment: 161 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 6
States / cities: Stamford, Connecticut • Miami, Florida • Pembroke Pines, Florida + 3 more

Conditions: Pain
Interventions: S-Caine™ Peel (lidocaine and tetracaine cream 7%/7%); Drug
Lead sponsor: ZARS Pharma Inc.; Industry
Eligibility: 0 Years to 17 Years
Enrollment: 80 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005
U.S. locations: 3
States / cities: Miami, Florida • The Bronx, New York • Nashville, Tennessee

Conditions: Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
Interventions: Biospecimen Collection, Bone Marrow Biopsy, Computed Tomography, Tafasitamab, Zanubrutinib; Procedure · Biological · Drug
Lead sponsor: City of Hope Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 26 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2027
U.S. locations: 3
States / cities: Duarte, California • Irvine, California • Miami, Florida

Conditions: Gastroesophageal Reflux Disease (GERD)
Interventions: Tegaserod; Drug
Lead sponsor: Novartis; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 30 participants
Timeline: 2004 – 2005
U.S. locations: 7
States / cities: Boynton Beach, Florida • Miami, Florida • Pembroke Pines, Florida + 4 more

Conditions: Alzheimer Disease
Interventions: Bryostatin 1, Placebo; Drug · Other
Lead sponsor: Neurotrope Bioscience, Inc.; Industry
Eligibility: 55 Years to 85 Years
Enrollment: 122 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2022
U.S. locations: 19
States / cities: Colton, California • San Diego, California • Atlantis, Florida + 16 more

Conditions: Asthma, Elevated Blood Eosinophils, Oral Corticosteroid Dependence
Interventions: Reslizumab, Placebo, Non-Oral Corticosteroid (non-OCS) Asthma Medication, Oral Corticosteroid (OCS); Drug
Lead sponsor: Teva Branded Pharmaceutical Products R&D, Inc.; Industry
Eligibility: 12 Years and older
Enrollment: 177 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2017
U.S. locations: 26
States / cities: Bakersfield, California • Long Beach, California • Clermont, Florida + 21 more

Conditions: Healthy
Interventions: SSP-004184SS; Drug
Lead sponsor: Shire; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 9 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013
U.S. locations: 1
States / cities: Miami, Florida

Conditions: Ulcerative Colitis
Interventions: Vixarelimab, Placebo; Drug
Lead sponsor: Genentech, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 79 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2025
U.S. locations: 15
States / cities: Camarillo, California • Los Angeles, California • Mission Hills, California + 12 more

Conditions: Stroke, Intracranial Atherosclerotic Stenosis (ICAS)
Interventions: MRI; Other
Lead sponsor: Yale University; Other
Eligibility: 18 Years and older
Enrollment: 300 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2029
U.S. locations: 28
States / cities: Birmingham, Alabama • Aurora, Colorado • Hartford, Connecticut + 24 more

Conditions: Diabetes Mellitus, Type 2
Interventions: Insulin icodec, Placebo insulin icodec, Insulin degludec, Placebo insulin degludec; Drug
Lead sponsor: Novo Nordisk A/S; Industry
Eligibility: 18 Years and older
Enrollment: 588 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2022
U.S. locations: 94
States / cities: Birmingham, Alabama • Guntersville, Alabama • Little Rock, Arkansas + 81 more

Conditions: Asthma
Interventions: Albuterol MDPI, Placebo, ProAir HFA inhaler; Drug
Lead sponsor: Teva Branded Pharmaceutical Products R&D, Inc.; Industry
Eligibility: 4 Years to 11 Years
Enrollment: 186 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2015
U.S. locations: 51
States / cities: Birmingham, Alabama • Mobile, Alabama • Little Rock, Alaska + 45 more

Conditions: Diabetes Mellitus, Ischemic Heart Disease
Interventions: 100 million Allogeneic Mesenchymal Human Stem Cells, Placebo; Drug · Other
Lead sponsor: Joshua M Hare; Other
Eligibility: 18 Years and older
Enrollment: 26 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2025
U.S. locations: 1
States / cities: Miami, Florida

Conditions: Type 2 Diabetes Mellitus
Interventions: Saxagliptin, Placebo; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 40 Years and older
Enrollment: 18,206 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2013
U.S. locations: 202
States / cities: Birmingham, Alabama • Phoenix, Arizona • Tempe, Arizona + 199 more

Conditions: Episodic Migraine
Interventions: BOTOX, Placebo; Drug
Lead sponsor: AbbVie; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 775 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2024
U.S. locations: 82
States / cities: Hoover, Alabama • Huntsville, Alabama • Phoenix, Arizona + 69 more

Conditions: Epilepsy
Interventions: Lacosamide; Drug
Lead sponsor: UCB BIOSCIENCES, Inc.; Industry
Eligibility: 16 Years to 70 Years
Enrollment: 426 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2012
U.S. locations: 108
States / cities: Alabaster, Alabama • Birmingham, Alabama • Huntsville, Alabama + 93 more

Conditions: Asthma
Interventions: Dupilumab, Placebo, Inhaled corticosteroid (ICS) therapy, Albuterol/Salbutamol, Levalbuterol/Levosalbutamol; Drug
Lead sponsor: Sanofi; Industry
Eligibility: 12 Years and older
Enrollment: 1,902 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2017
U.S. locations: 116
States / cities: Birmingham, Alabama • Flagstaff, Arizona • Gilbert, Arizona + 100 more

Conditions: Venous Leg Ulcer, Venous Stasis Ulcer
Interventions: No HP802 Treatment, No HP802 Vehicle Treatment; Biological · Other
Lead sponsor: Healthpoint; Industry
Eligibility: 18 Years and older
Enrollment: 206 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2012
U.S. locations: 29
States / cities: Tucson, Arizona • Castro Valley, California • Encinitas, California + 26 more

Conditions: HIV Infections
Interventions: GW695634; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years and older
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2004
U.S. locations: 18
States / cities: Phoenix, Arizona • Fountain Valley, California • San Francisco, California + 15 more

Conditions: Idiopathic Intracranial Hypertension
Interventions: Acetazolamide, Placebo, Formal weight loss counselling program; Drug · Behavioral
Lead sponsor: St. Luke's-Roosevelt Hospital Center; Other
Eligibility: 18 Years to 60 Years
Enrollment: 165 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010 – 2014
U.S. locations: 39
States / cities: Birmingham, Alabama • Los Angeles, California • Waterbury, Connecticut + 31 more

Conditions: Cutaneous Lupus Erythematosus (CLE), Systemic Lupus Erythematosus, SLE, SLE (Systemic Lupus), CLE
Interventions: VENT-03, Placebo; Drug
Lead sponsor: Ventus Therapeutics U.S., Inc.; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 15
States / cities: Beverly Hills, California • Clearwater, Florida • DeBary, Florida + 12 more

Conditions: Diabetes, Hypoglycemia
Interventions: BHT-3021, BHT-Placebo; Drug
Lead sponsor: Bayhill Therapeutics; Industry
Eligibility: 18 Years and older
Enrollment: 80 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2011
U.S. locations: 10
States / cities: Birmingham, Alabama • Fresno, California • Aurora, Colorado + 7 more

Conditions: HIV Infections
Interventions: Pravastatin sodium, Simvastatin, Atorvastatin calcium, Ritonavir, Nelfinavir mesylate, Saquinavir; Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 60 Years
Enrollment: 56 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: Ends 2002
U.S. locations: 13
States / cities: Los Angeles, California • San Francisco, California • Stanford, California + 10 more

Conditions: HIV Infections
Interventions: CAB LA + RPV LA, Oral ART; Drug
Lead sponsor: ViiV Healthcare; Industry
Eligibility: 12 Years and older
Enrollment: 326 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2028
U.S. locations: 39
States / cities: Birmingham, Alabama • Los Angeles, California • Aurora, Colorado + 29 more

Conditions: Hiv, Hpv
Interventions: Self-Collection HPV testing kit from Abbott; Diagnostic Test
Lead sponsor: University of California, Los Angeles; Other
Eligibility: 21 Years to 40 Years · Female only
Enrollment: 650 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2029
U.S. locations: 9
States / cities: Denver, Colorado • Miami, Florida • Chicago, Illinois + 5 more

Search by objective public record fields.

A Study Investigating Intravenous Human Normal Immune Globulin (IGIV) 10% KIg10 (QIVIGY) in Subjects With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)

Safety Study of S-Caine Peel (Skin Numbing Cream) Before a Painful Dermatologic Procedure in Children

Tafasitamab and Zanubrutinib for the Treatment of Patients With Newly Diagnosed Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma, TaZA CLL Study

Assessment of the Role of Tegaserod Therapy in the Management of Gastroesophageal Reflux Disease (GERD) Symptoms in Patients With Incomplete Response to Proton Pump Inhibitors (PPIs).

Bryostatin Treatment of Moderately Severe Alzheimer's Disease

An Efficacy and Safety Study of Reslizumab Subcutaneous in Patients With Oral Corticosteroid Dependent Asthma and Elevated Blood Eosinophils

The Effect of Food on the Bioavailability of a Single Dose of SSP-004184SS in Healthy Adult Subjects

A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Vixarelimab in Participants With Moderate to Severe Ulcerative Colitis (UC)

Comparison of Anti-coagulation and Anti-Platelet Therapies for Intracranial Vascular Atherostenosis- Magnetic Resonance Imaging

A Research Study to Compare Two Types of Insulin, a New Insulin, Insulin Icodec and an Available Insulin, Insulin Degludec, in People With Type 2 Diabetes Who Have Not Used Insulin Before (ONWARDS 3)

A Chronic-Dose Safety and Efficacy Study of Albuterol Multi-Dose Dry Powder Inhaler in Pediatric Asthmatics

Allogeneic Mesenchymal Human Stem Cell Infusion Therapy for Endothelial DySfunctiOn in Diabetic Subjects With Symptomatic Ischemic Heart Disease. (ACESO-IHD)

Does Saxagliptin Reduce the Risk of Cardiovascular Events When Used Alone or Added to Other Diabetes Medications

Study of BOTOX Injections in Prevention of Migraine in Adult Participants With Episodic Migraine

Trial to Demonstrate the Efficacy and Safety of Conversion to Lacosamide Monotherapy for Partial-onset Seizures

Evaluation of Dupilumab in Patients With Persistent Asthma (Liberty Asthma Quest)

Safety Follow-Up to HP 802-247-09-015

Monotherapy Versus Placebo Over 7 Days-Non-Nucleoside Reverse Transcriptase Inhibitor-Experienced HIV1 Infected Adults

Idiopathic Intracranial Hypertension Treatment Trial

A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase 2a Study With an Open-Label Extension Evaluating the Efficacy and Safety of VENT-03 in Adult Participants With Active Cutaneous Lupus Erythematosus With or Without Systemic Lupus Erythematosus

Phase 1 Study of BHT-3021 in Subjects With Type 1 Diabetes Mellitus

A Study on Possible Interactions Between Protease Inhibitors (Anti-HIV Drugs) and Drugs Which Lower the Level of Fat in Your Blood

A Study to Evaluate the Effectiveness of Long-acting (LA) Cabotegravir (CAB) + Rilpivirine (RPV) LA When Given to Participants With Detectable HIV-1

Real-world Effectiveness of HPV Vaccine in Women Living With HIV and Its Impact on Cervical Cancer Screening Accuracies